| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1026482268 |
| P356 | DOI | 10.1186/S13023-015-0310-1 |
| P932 | PMC publication ID | 4524368 |
| P698 | PubMed publication ID | 26238698 |
| P5875 | ResearchGate publication ID | 281816894 |
| P50 | author | Kathryn Stowell | Q52145973 |
| Anja H Schiemann | Q73905694 | ||
| P2093 | author name string | Henry Rosenberg | |
| Neil Pollock | |||
| Terasa Bulger | |||
| P2860 | cites work | Lessons from calsequestrin-1 ablation in vivo: much more than a Ca(2+) buffer after all | Q82749646 |
| Ryanodinopathies: RyR-Linked Muscle Diseases | Q83483025 | ||
| Next-generation DNA sequencing of a Swedish malignant hyperthermia cohort | Q85638834 | ||
| Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells | Q86267085 | ||
| [Helsinki Declaration on Patient Safety in Anaesthesiology - Part 3: SOP for malignant hyperthermia] | Q86606617 | ||
| Malignant hyperthermia | Q93658097 | ||
| Endocrine and metabolic disorders in anaesthesia and intensive care | Q95789732 | ||
| Central core disease | Q21202972 | ||
| Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy | Q24294570 | ||
| JP-45/JSRP1 variants affect skeletal muscle excitation-contraction coupling by decreasing the sensitivity of the dihydropyridine receptor | Q24297615 | ||
| Agonist-activated Ca2+ influx occurs at stable plasma membrane and endoplasmic reticulum junctions | Q24306442 | ||
| Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle | Q24308714 | ||
| Junctin and the histidine-rich Ca2+ binding protein: potential roles in heart failure and arrhythmogenesis | Q24320070 | ||
| Junctophilin 1 and 2 proteins interact with the L-type Ca2+ channel dihydropyridine receptors (DHPRs) in skeletal muscle | Q24624889 | ||
| Temperature monitoring and perioperative thermoregulation | Q24653479 | ||
| Central core disease: clinical, pathological, and genetic features | Q24675329 | ||
| Recommendations for returning genomic incidental findings? We need to talk! | Q26995124 | ||
| Disease mutations in the ryanodine receptor central region: crystal structures of a phosphorylation hot spot domain | Q27681194 | ||
| Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1) | Q28363303 | ||
| Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice | Q28511309 | ||
| An Ryr1I4895T mutation abolishes Ca2+ release channel function and delays development in homozygous offspring of a mutant mouse line | Q28586418 | ||
| The junctional SR protein JP-45 affects the functional expression of the voltage-dependent Ca2+ channel Cav1.1 | Q28587534 | ||
| Skeletal muscle-specific T-tubule protein STAC3 mediates voltage-induced Ca2+ release and contractility | Q28588104 | ||
| SIFT: Predicting amino acid changes that affect protein function | Q29547211 | ||
| Epigenetic changes as a common trigger of muscle weakness in congenital myopathies | Q29977760 | ||
| Automated inference of molecular mechanisms of disease from amino acid substitutions. | Q30380440 | ||
| Exome sequencing reveals novel rare variants in the ryanodine receptor and calcium channel genes in malignant hyperthermia families | Q30426901 | ||
| Orai1-dependent calcium entry promotes skeletal muscle growth and limits fatigue | Q30560181 | ||
| Using exome data to identify malignant hyperthermia susceptibility mutations | Q30689554 | ||
| Porcine malignant hyperthermia: critical temperatures for in vivo and in vitro responses. | Q41239461 | ||
| Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update. | Q41595225 | ||
| A novel device for target controlled administration and reflection of desflurane--the Mirus™. | Q41960498 | ||
| Functional properties of ryanodine receptors carrying three amino acid substitutions identified in patients affected by multi-minicore disease and central core disease, expressed in immortalized lymphocytes | Q41996021 | ||
| Masseter spasm with anesthesia: incidence and implications | Q42250947 | ||
| The incidence of masseter muscle rigidity after succinylcholine in infants and children | Q42284014 | ||
| Predicting functional effect of human missense mutations using PolyPhen-2. | Q42406410 | ||
| The calmodulin binding region of the skeletal ryanodine receptor acts as a self-modulatory domain | Q42616593 | ||
| Recessive RYR1 mutations cause unusual congenital myopathy with prominent nuclear internalization and large areas of myofibrillar disorganization | Q42681353 | ||
| Exertional rhabdomyolysis and malignant hyperthermia in a patient with ryanodine receptor type 1 gene, L-type calcium channel alpha-1 subunit gene, and calsequestrin-1 gene polymorphisms | Q43221984 | ||
| CASQ1 gene is an unlikely candidate for malignant hyperthermia susceptibility in the North American population | Q43479454 | ||
| Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis | Q43514682 | ||
| Incidence of malignant hyperthermia in Denmark | Q43638292 | ||
| Malignant hyperthermia and apparent heat stroke | Q43670218 | ||
| Hyperkalemia, verapamil, and dantrolene | Q43678835 | ||
| Epigenetic allele silencing and variable penetrance of malignant hyperthermia susceptibility | Q43701462 | ||
| Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia. | Q43748398 | ||
| Anaesthetic uptake and washout characteristics of patient circuit tubing with special regard to current decontamination techniques | Q43881316 | ||
| Delayed postoperative rhabdomyolysis in a patient subsequently diagnosed as malignant hyperthermia susceptible | Q43901898 | ||
| Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia? | Q43986779 | ||
| Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. | Q44029435 | ||
| Serotonin toxicity and malignant hyperthermia: role of 5-HT2 receptors | Q44029460 | ||
| Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor | Q44094526 | ||
| Suspected malignant hyperthermia reactions in New Zealand. | Q44103438 | ||
| Presence of two different genetic traits in malignant hyperthermia families: implication for genetic analysis, diagnosis, and incidence of malignant hyperthermia susceptibility | Q44201904 | ||
| Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? | Q44407009 | ||
| S-glutathionylation decreases Mg2+ inhibition and S-nitrosylation enhances Ca2+ activation of RyR1 channels | Q44550513 | ||
| The role of sympathetic activity in initiating malignant hyperthermia | Q44686206 | ||
| Stress-induced increase in skeletal muscle force requires protein kinase A phosphorylation of the ryanodine receptor | Q44740208 | ||
| N-terminal region of FKBP12 is essential for binding to the skeletal ryanodine receptor. | Q44807437 | ||
| Ascending tonic-clonic syndrome secondary to intrathecal Omnipaque | Q44984518 | ||
| Comparative analysis of in vitro contracture tests with ryanodine and a combination of ryanodine with either halothane or caffeine: a comparative investigation in malignant hyperthermia | Q45021452 | ||
| Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families | Q45126860 | ||
| Dyspedic mouse skeletal muscle expresses major elements of the triadic junction but lacks detectable ryanodine receptor protein and function | Q45256995 | ||
| Hyperkalemic cardiac arrest after cardiopulmonary bypass in a child with unsuspected duchenne muscular dystrophy | Q45280365 | ||
| Screening of the entire ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the north american population | Q45282848 | ||
| The psychological dimension of informed consent: dissonance processes in genetic testing | Q45292992 | ||
| Categorizing genetic tests to identify their ethical, legal, and social implications | Q45305010 | ||
| Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. | Q45821365 | ||
| Malignant hyperthermia on ICU – sudden attack of the “snake”. | Q46172931 | ||
| Muscle biopsy and in vitro contracture test in subjects with idiopathic HyperCKemia. | Q46350465 | ||
| King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene. | Q46395272 | ||
| PMUT: a web-based tool for the annotation of pathological mutations on proteins. | Q46477731 | ||
| Short-term sevoflurane sedation using the Anaesthetic Conserving Device after cardiothoracic surgery | Q46578374 | ||
| Junctate, an inositol 1,4,5-triphosphate receptor associated protein, is present in rodent sperm and binds TRPC2 and TRPC5 but not TRPC1 channels. | Q46695331 | ||
| Identification and biochemical characterization of a novel ryanodine receptor gene mutation associated with malignant hyperthermia | Q46796424 | ||
| Heat- and anesthesia-induced malignant hyperthermia in an RyR1 knock-in mouse. | Q46801191 | ||
| Sevoflurane is less sensitive than halothane for in vitro detection of malignant hyperthermia susceptibility | Q47749572 | ||
| Functional characterisation of the R2452W ryanodine receptor variant associated with malignant hyperthermia susceptibility. | Q47834611 | ||
| Clarifying the role of activated charcoal filters in preparing an anaesthetic workstation for malignant hyperthermia-susceptible patients. | Q47919022 | ||
| Health worker exposure risk during inhalation sedation with sevoflurane using the (AnaConDa®) anaesthetic conserving device | Q47923256 | ||
| Functional characterization of 2 known ryanodine receptor mutations causing malignant hyperthermia. | Q47933738 | ||
| Volatile isoflurane sedation in cerebrovascular intensive care patients using AnaConDa(®): effects on cerebral oxygenation, circulation, and pressure | Q48120718 | ||
| Ecstacy-induced delayed rhabdomyolysis and neuroleptic malignant syndrome in a patient with a novel variant in the ryanodine receptor type 1 gene | Q48151960 | ||
| Preparation of Datex-Ohmeda Aestiva and Aisys anaesthetic machines for use in malignant hyperthermia susceptible patients. | Q48163267 | ||
| Malignant hyperthermia: human stress triggering | Q48238790 | ||
| John H. Eisenach, M.D., recipient of the 2008 Presidential Scholar Award | Q48320216 | ||
| Prevalence of malignant hyperthermia due to anesthesia in New York State, 2001-2005. | Q48406847 | ||
| Cardiac arrests and deaths associated with malignant hyperthermia in north america from 1987 to 2006: a report from the north american malignant hyperthermia registry of the malignant hyperthermia association of the United States | Q48506656 | ||
| Masseter muscle rigidity associated with glycine1306-to-alanine mutation in the adult muscle sodium channel alpha-subunit gene | Q49251027 | ||
| Ca2+ store determines gating of store operated calcium entry in mammalian skeletal muscle | Q50086372 | ||
| STIM1 negatively regulates Ca²⁺ release from the sarcoplasmic reticulum in skeletal myotubes | Q50998521 | ||
| Multiple interacting gene products may influence susceptibility to malignant hyperthermia. | Q51354595 | ||
| A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. | Q51392443 | ||
| Malignant hyperthermia in infancy and identification of novel RYR1 mutation. | Q51400416 | ||
| In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group. | Q51536228 | ||
| Clinical reassessment of malignant hyperthermia in Abitibi-Témiscamingue. | Q51539915 | ||
| Activated charcoal effectively removes inhaled anesthetics from modern anesthesia machines | Q40326035 | ||
| Ca2+ signaling in HEK-293 and skeletal muscle cells expressing recombinant ryanodine receptors harboring malignant hyperthermia and central core disease mutations. | Q40462256 | ||
| Detection of proton release from cultured human myotubes to identify malignant hyperthermia susceptibility | Q40623830 | ||
| Malignant hyperthermia: a review of published cases | Q40832265 | ||
| SRP-27 is a novel component of the supramolecular signalling complex involved in skeletal muscle excitation-contraction coupling. | Q33307042 | ||
| TRPC3-interacting triadic proteins in skeletal muscle | Q33316168 | ||
| The role of CACNA1S in predisposition to malignant hyperthermia | Q33510262 | ||
| Ryanodine receptor mutations in malignant hyperthermia and central core disease | Q33903152 | ||
| A malignant hyperthermia-inducing mutation in RYR1 (R163C): alterations in Ca2+ entry, release, and retrograde signaling to the DHPR. | Q33922807 | ||
| A malignant hyperthermia-inducing mutation in RYR1 (R163C): consequent alterations in the functional properties of DHPR channels | Q33922848 | ||
| Serotonin syndrome and other serotonergic disorders | Q33967265 | ||
| Malignant hyperthermia: advances in clinical management and diagnosis | Q33992099 | ||
| Abnormal intracellular ca(2+)homeostasis and disease | Q34003108 | ||
| Store-operated Ca2+ entry in malignant hyperthermia-susceptible human skeletal muscle. | Q34055934 | ||
| RYR1 mutations causing central core disease are associated with more severe malignant hyperthermia in vitro contracture test phenotypes | Q34139686 | ||
| Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review | Q34140813 | ||
| Functional Defects in Six Ryanodine Receptor Isoform-1 (RyR1) Mutations Associated with Malignant Hyperthermia and Their Impact on Skeletal Excitation-Contraction Coupling | Q34195030 | ||
| Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families | Q34216462 | ||
| Effect of prior exercise on thermal sensitivity of malignant hyperthermia-susceptible muscle | Q34307851 | ||
| Functional analysis of the R1086H malignant hyperthermia mutation in the DHPR reveals an unexpected influence of the III-IV loop on skeletal muscle EC coupling. | Q34327401 | ||
| A clinical grading scale to predict malignant hyperthermia susceptibility | Q34329778 | ||
| Phosphorylation of serine 2843 in ryanodine receptor-calcium release channel of skeletal muscle by cAMP-, cGMP- and CaM-dependent protein kinase | Q34355057 | ||
| Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle | Q34368458 | ||
| Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation. | Q34384665 | ||
| The sensitivity and specificity of the caffeine-halothane contracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. | Q34462229 | ||
| Central core disease is due to RYR1 mutations in more than 90% of patients. | Q34514718 | ||
| Ca2+ release in muscle fibers expressing R4892W and G4896V type 1 ryanodine receptor disease mutants | Q34545457 | ||
| Pathophysiological role of the serotonin system in malignant hyperthermia | Q34552183 | ||
| Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing | Q34567866 | ||
| Pharmacologic and functional characterization of malignant hyperthermia in the R163C RyR1 knock-in mouse | Q34583987 | ||
| Heat stroke: implications for critical care and anaesthesia | Q34687446 | ||
| Coverage bias and sensitivity of variant calling for four whole-genome sequencing technologies | Q34776833 | ||
| Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry | Q34863829 | ||
| Stac adaptor proteins regulate trafficking and function of muscle and neuronal L-type Ca2+ channels | Q34985729 | ||
| Functional annotations improve the predictive score of human disease-related mutations in proteins | Q34985914 | ||
| Fatal malignant hyperthermia-like syndrome with rhabdomyolysis complicating the presentation of diabetes mellitus in adolescent males | Q35141281 | ||
| Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathies | Q35209452 | ||
| Results of in vitro contracture tests for the diagnosis of malignant hyperthermia susceptibility in monozygote twins. | Q51541098 | ||
| Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. | Q51554106 | ||
| Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family. | Q51579632 | ||
| Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis. | Q51633148 | ||
| Rhabdomyolysis and acute renal failure in unsuspected malignant hyperpyrexia. | Q51662252 | ||
| Improved noninvasive diagnostic testing for malignant hyperthermia susceptibility from a combination of metabolites determined in vivo with 31P-magnetic resonance spectroscopy. | Q51665029 | ||
| Malignant hyperthermia: halothane- and calcium-induced calcium release in skeletal muscle | Q51671473 | ||
| Sources of variability in halothane and caffeine contracture tests for susceptibility to malignant hyperthermia | Q51684557 | ||
| Prediction of malignant hyperthermia susceptibility in low-risk subjects. An epidemiologic investigation of caffeine halothane contracture responses. The North American Malignant Hyperthermia Registry. | Q51698452 | ||
| Muscle activity, pH and malignant hyperthermia. | Q51712413 | ||
| Fatty acids markedly lower the threshold for halothane-induced calcium release from the terminal cisternae in human and porcine normal and malignant hyperthermia susceptible skeletal muscle. | Q51719802 | ||
| Anesthesia in malignant hyperthermia susceptible patients. | Q51744327 | ||
| Malignant hyperthermia: slow sodium current in cultured human muscle cells. | Q51748544 | ||
| Human malignant hyperthermia: awake episodes and correction by dantrolene. | Q51876463 | ||
| Two central core disease (CCD) deletions in the C-terminal region of RYR1 alter muscle excitation-contraction (EC) coupling by distinct mechanisms. | Q52573383 | ||
| Anesthetic-induced malignant hyperpyrexia in children. | Q52729480 | ||
| King–Denborough syndrome with and without mutations in the skeletal muscle ryanodine receptor (RYR1) gene | Q57053868 | ||
| Prediction of Malignant Hyperthermia Susceptibility in Low-risk Subjects An Epidemiologic Investigation of Caffeine Halothane Contracture Responses | Q57529662 | ||
| Heat stroke and malignant hyperpyrexia | Q70378972 | ||
| A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group | Q70639436 | ||
| Malignant hyperthermia masked by capnographic monitoring | Q72246225 | ||
| Should we use muscle biopsy to diagnose malignant hyperthermia susceptibility? | Q72860449 | ||
| A multicenter study of 4-chloro-m-cresol for diagnosing malignant hyperthermia susceptibility | Q73332927 | ||
| Hemodynamic and metabolic alterations in response to graded exercise in a patient susceptible to malignant hyperthermia | Q73363900 | ||
| Perioperative severe rhabdomyolysis revealing susceptibility to malignant hyperthermia | Q74110539 | ||
| Dantrolene in malignant hyperthermia (MH)-susceptible patients with exaggerated exercise stress | Q74254707 | ||
| Malignant hyperthermia | Q79074845 | ||
| Malignant hyperthermia and central core disease causative mutations in Swedish patients | Q79324990 | ||
| In vivo and in vitro characterization of skeletal muscle metabolism in patients with statin-induced adverse effects | Q80016136 | ||
| Native American myopathy: congenital myopathy with cleft palate, skeletal anomalies, and susceptibility to malignant hyperthermia | Q81454581 | ||
| Epigenetic allele silencing unveils recessive RYR1 mutations in core myopathies | Q35221453 | ||
| Type 1 ryanodine receptor knock-in mutation causing central core disease of skeletal muscle also displays a neuronal phenotype | Q35673620 | ||
| Gene dose influences cellular and calcium channel dysregulation in heterozygous and homozygous T4826I-RYR1 malignant hyperthermia-susceptible muscle | Q35704843 | ||
| Next-generation Sequencing of RYR1 and CACNA1S in Malignant Hyperthermia and Exertional Heat Illness | Q35756769 | ||
| Mice expressing T4826I-RYR1 are viable but exhibit sex- and genotype-dependent susceptibility to malignant hyperthermia and muscle damage | Q35787753 | ||
| Temperature and RyR1 regulate the activation rate of store-operated Ca²+ entry current in myotubes | Q36105323 | ||
| Triadin binding to the C-terminal luminal loop of the ryanodine receptor is important for skeletal muscle excitation contraction coupling | Q36296083 | ||
| Complications associated with the administration of dantrolene 1987 to 2006: a report from the North American Malignant Hyperthermia Registry of the Malignant Hyperthermia Association of the United States | Q36398823 | ||
| Mutations in RYR1 in malignant hyperthermia and central core disease | Q36569488 | ||
| Nonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia | Q36615166 | ||
| Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression | Q36665389 | ||
| The skeletal L-type Ca(2+) current is a major contributor to excitation-coupled Ca(2+) entry | Q37023260 | ||
| Advanced technologies and devices for inhalational anesthetic drug dosing | Q37050418 | ||
| A retrograde signal from RyR1 alters DHP receptor inactivation and limits window Ca2+ release in muscle fibers of Y522S RyR1 knock-in mice | Q37132911 | ||
| A recessive ryanodine receptor 1 mutation in a CCD patient increases channel activity | Q37142856 | ||
| Checking your SOCCs and feet: the molecular mechanisms of Ca2+ entry in skeletal muscle | Q37305499 | ||
| Calsequestrin-1: a new candidate gene for malignant hyperthermia and exertional/environmental heat stroke | Q37471099 | ||
| Inhalational anesthesia vs total intravenous anesthesia (TIVA) for pediatric anesthesia. | Q37488453 | ||
| Regulation of the skeletal muscle ryanodine receptor/Ca2+-release channel RyR1 by S-palmitoylation | Q37653345 | ||
| Malignant hyperthermia: pharmacology of triggering | Q37882233 | ||
| Dominant and recessive RYR1 mutations in adults with core lesions and mild muscle symptoms. | Q37889772 | ||
| Core myopathies | Q37968743 | ||
| Minimally invasive metabolic testing for malignant hyperthermia susceptibility: a systematic review of the methodology and results | Q38088716 | ||
| Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands | Q38120619 | ||
| Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients | Q38121132 | ||
| Exertional heat stroke, rhabdomyolysis and susceptibility to malignant hyperthermia. | Q38134154 | ||
| DNA testing for malignant hyperthermia: the reality and the dream | Q38180343 | ||
| Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States | Q38255512 | ||
| Genetics professionals' opinions of whole-genome sequencing in the newborn period | Q39107529 | ||
| Genetic counselors' views and experiences with the clinical integration of genome sequencing | Q39222177 | ||
| Sequence capture and massively parallel sequencing to detect mutations associated with malignant hyperthermia. | Q39266388 | ||
| Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA. | Q39704856 | ||
| Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease. | Q39741966 | ||
| Functional characterization of ryanodine receptor (RYR1) sequence variants using a metabolic assay in immortalized B-lymphocytes | Q39887722 | ||
| Reduced threshold for luminal Ca2+ activation of RyR1 underlies a causal mechanism of porcine malignant hyperthermia | Q39978369 | ||
| Characterization of recessive RYR1 mutations in core myopathies | Q40238382 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malignant hyperthermia | Q1585081 |
| P304 | page(s) | 93 | |
| P577 | publication date | 2015-08-04 | |
| P1433 | published in | Orphanet Journal of Rare Diseases | Q15756117 |
| P1476 | title | Malignant hyperthermia: a review | |
| P478 | volume | 10 |
| Q90231956 | A Case Report of Suspected Malignant Hyperthermia: How Will the Diagnosis Affect a Patient's Insurability? |
| Q64258623 | A Novel Dantrolene Sodium-Loaded Mixed Micelle Containing a Small Amount of Cremophor EL: Characterization, Stability, Safety and Pharmacokinetics |
| Q39353671 | A clinical review of inhalation anesthesia with sevoflurane: from early research to emerging topics |
| Q89033581 | A comprehensive review of malignant hyperthermia: Preventing further fatalities in orthopedic surgery |
| Q90717797 | Abnormal calcium signalling and the caffeine-halothane contracture test |
| Q100512261 | Adaptive thermogenesis enhances the life-threatening response to heat in mice with an Ryr1 mutation |
| Q38714784 | An approach to iatrogenic deaths |
| Q56668469 | Anesthesia for patients with mutations: a case report |
| Q38816760 | Anesthetic management of 877 pediatric patients undergoing muscle biopsy for neuromuscular disorders: a 20-year review |
| Q42024571 | Assessing anesthetic activity through modulation of the membrane dipole potential. |
| Q33755195 | Calcium Dynamics Mediated by the Endoplasmic/Sarcoplasmic Reticulum and Related Diseases |
| Q64120597 | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes |
| Q89629441 | Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients |
| Q45869436 | Clinicopathologic Conference: A Newborn With Hypotonia, Cleft Palate, Micrognathia, and Bilateral Club Feet. |
| Q57455206 | Comparison of chlorantraniliprole and flubendiamide activity towards wild type and malignant hyperthermia-susceptible ryanodine receptors and heat stress intolerance |
| Q30008804 | Congenital myopathy results from misregulation of a muscle Ca2+ channel by mutant Stac3. |
| Q39216231 | Counter-flow suggests transport of dantrolene and 5-OH dantrolene by the organic anion transporters 2 (OAT2) and 3 (OAT3). |
| Q90615429 | Crystal structure of diamondback moth ryanodine receptor Repeat34 domain reveals insect-specific phosphorylation sites |
| Q43083675 | Dantrolene requires Mg2+ to arrest malignant hyperthermia |
| Q47251109 | Delayed Development of Malignant Hyperthermia Following Cardiopulmonary Bypass |
| Q61453191 | Difficult airway management and suspected malignant hyperthermia in a Child with Cri Du Chat Syndrome |
| Q90151314 | Early Recognition and Treatment of Malignant Hyperthermia in Pediatric Patient during Bronchoscopy |
| Q39146069 | Exertional rhabdomyolysis and heat stroke: Beware of volatile anesthetic sedation |
| Q92979212 | Febrile convulsions during recovery after anesthesia in an infant with history of MMR vaccination: A case report |
| Q41781551 | Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia |
| Q48222125 | Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia |
| Q57113331 | Hyperthermia associated with biliary obstruction during living donor liver transplantation |
| Q55119914 | Impact of Different Serum Potassium Levels on Postresuscitation Heart Function and Hemodynamics in Patients with Nontraumatic Out-of-Hospital Cardiac Arrest. |
| Q59794833 | In vitro effects of levosimendan on muscle of malignant hyperthermia susceptible and non-susceptible swine |
| Q57568708 | Inhalative Analgosedierung auf der Intensivstation |
| Q92430344 | Interactions among ryanodine receptor isotypes contribute to muscle fiber type development and function |
| Q94508917 | Intracellular calcium leak lowers glucose storage in human muscle, promoting hyperglycemia and diabetes |
| Q48110785 | Intracellular thermometry with fluorescent sensors for thermal biology. |
| Q90717865 | Is malignant hyperthermia associated with hyperglycaemia? |
| Q47324823 | JSA guideline for the management of malignant hyperthermia crisis 2016. |
| Q64234641 | Life-threatening Episodes of Malignant Hyperthermia Following Halothane Anesthesia in Three Children: A Case Series and Review of Literature |
| Q89779023 | MALIGNANT HYPERTHERMIA IN A CHILD AFTER MAGNETIC RESONANCE IMAGING: A CASE REPORT |
| Q47253099 | Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on an Old Concept |
| Q92433473 | Malignant hyperthermia in a 4-year-old girl during anesthesia induction with sevoflurane and succinylcholine for congenital ptosis surgery |
| Q38888258 | Malignant hyperthermia susceptibility in patients with exertional rhabdomyolysis: a retrospective cohort study and updated systematic review. |
| Q40102418 | Malignant hyperthermia syndrome in the intensive care unit : Differential diagnosis and acute measures |
| Q58745577 | Multidisciplinary Perioperative Care for Children with Neuromuscular Disorders |
| Q38746169 | Neurologic Complications of Commonly Used Drugs in the Hospital Setting |
| Q52647770 | Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings. |
| Q33587432 | Novel mutation identified in severe early-onset tumor necrosis factor receptor-associated periodic syndrome: a case report |
| Q50052115 | Pathophysiology of heatstroke in dogs - revisited |
| Q28074804 | PharmGKB summary: very important pharmacogene information for RYR1 |
| Q64108006 | Pharmacogenomics of inhalational anesthetic agents |
| Q92798933 | Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
| Q92777582 | Prevalence of malignant hyperthermia diagnosis in obstetric patients in the United States, 2003 to 2014 |
| Q49577286 | Reduced threshold for store overload-induced Ca2+ release is a common defect of RyR1 mutations associated with malignant hyperthermia and central core disease |
| Q38713977 | Role of SERCA Pump in Muscle Thermogenesis and Metabolism |
| Q38692315 | Round Table on Malignant Hyperthermia in Physically Active Populations: Meeting Proceedings |
| Q90345436 | Single Amino Acid Changes in the Ryanodine Receptor in the Human Population Have Effects In Vivo on Caenorhabditis elegans Neuro-Muscular Function |
| Q42804825 | Skeletal Muscle Thermogenesis and Its Role in Whole Body Energy Metabolism |
| Q50555368 | Stocks of dantrolene in anesthesia and intensive care units in Germany : Nationwide online survey with 1673 participants |
| Q47300757 | Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia |
| Q57656681 | Structural Details of the Ryanodine Receptor Calcium Release Channel and Its Gating Mechanism |
| Q98771050 | Succinylcholine-Induced Masseter Muscle Rigidity Successfully Managed With Propofol and Laryngeal Mask Airway: A Case Report and Brief Review |
| Q47235382 | Sudden death due to malignant hyperthermia with a mutation of RYR1: autopsy, morphology and genetic analysis. |
| Q47625165 | Targeting thermogenesis in brown fat and muscle to treat obesity and metabolic disease. |
| Q47241038 | The Role of GABA Receptor Agonists in Anesthesia and Sedation |
| Q47213395 | The pharmacogenetics of medications used in general anesthesia |
| Q94560954 | Thermal Activation of Thin Filaments in Striated Muscle |
| Q92881844 | Treatment of Satoyoshi syndrome: a systematic review |
| Q47986797 | Unexpected Cause of Rhabdomyolysis and Proximal Muscle Weakness |
| Q88670767 | Using eye tracking technology to compare the effectiveness of malignant hyperthermia cognitive aid design |
| Q41009099 | Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency and Perioperative Management in Adult Patients |
| Q47220248 | Voltage modulates halothane-triggered Ca2+ release in malignant hyperthermia-susceptible muscle |
| Q53900904 | [Abortive course of malignant hyperthermia following preclinical induction of general anesthesia using succinylcholine]. |
Search more.